Correlation Between Selected Prognostic Factors and Postoperative Course in Liver Transplant Recipients

Transplantation Proceedings

Volumn 41, Issue 8, 2009, Pages 3091-3102

  Patkowski, W ^a   Zieniewicz, K ^a   Skalski, M ^a   Krawczyk, M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; UREA;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; BILIARY TRACT DRAINAGE; COLD ISCHEMIA; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PEROPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; SURVIVAL TIME;

ADULT; AGED; BLOOD TRANSFUSION; FEMALE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HEPATITIS, AUTOIMMUNE; HUMANS; INTRAOPERATIVE COMPLICATIONS; LIVER DISEASES, ALCOHOLIC; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS;

EID: 70350500168     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.09.038     Document Type: Article

References (52)

1. Gines P. Compensated cirrhosis: Natural history and prognostic factors. Hepatology 7 (1987) 122
2. Saunders B. 20-year prospective study of cirrhosis. Br Med J 282 (1981) 263
3. Stell A.D., McAlister V.C., and Thorburn D. A comparison of disease severity and survival rates after liver transplantation in the United Kingdom, Canada, and the United States. Liver Transpl 7 (2004) 898
4. Burroughs A.K., Sabin C.A., Rolles K., et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 367 (2006) 225
5. Ziser A., Plevak D.J., and Wiesner R.H. Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology 90 (1999) 42
6. Aranha G.V., and Greenlee H.B. Intraabdominal surgery in patients with advanced cirrhosis. Arch Surg 121 (1986) 275
7. Child C.G., and Turcotte J.G. Surgery and portal hypertension. The liver and portal hypertension (1964), WB Saunders, Philadelphia 50
8. Puch R.N., Murray-Lyon I.M., and Dawson J.L. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973) 646
9. Merion R.M., Schaubel D.E., Dykstra D.M., et al. The survival benefit of liver transplantation. Am J Transpl 5 (2005) 307
10. Vogt D.P., Henderson J.M., and Carey W.D. The long-term survival and cause of death in patients who survive at least 1 year after liver transplantation. Surgery 132 (2002) 775
11. Wiesner R., Lake J.R., Freeman R.B., et al. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl 12 (2006) 85
12. Saab S., Wang V., Ibrahim A.B., et al. MELD score predicts 1-year patient survival post- orthotopic liver transplantation. Liver Transpl 5 (2003) 473
13. Saab S., Ibrahim A.B., Shpaner A., et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl 11 (2005) 218
14. Burroughs A.K., Sabin C.A., Rolles K., et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 367 (2006) 225
15. Freeman R.B., Gish R.G., Harper A., et al. Model for End-Stage Liver Disease (MELD) Exception guidelines: results and recommendations from the MELD Exception Study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 12 (2006) 128
16. Freeman R.B., Wiesner R.H., Harper A., et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 8 (2002) 851
17. Edwards E., and Harper A. Does MELD work for relisted candidates?. Liver Transpl 10 (2004) 10
18. Thuluvath P.J., Yoo H.Y., and Thompson R.E. A model to predict survival at one month, one year, and five years after liver transplantation based on pretransplant clinical characteristics. Liver Transpl 5 (2003) 527
19. McDiarmid S., Gish R.G., Horslen S., et al. Model for End-Stage Liver Disease (MELD). Exception for unusual metabolic liver diseases. Liver Transpl 12 (2006) S124
20. Sheiner P., Gish R.G., and Sanyal A. Model for End-Stage Liver Disease (MELD). Exception for portal hypertensive gastrointestinal bleeding. Liver Transpl 12 (2006) S112
21. Washburn W.K., and Gis R.G. Model for End-Stage Liver Disease (MELD). Exception for severe pruritus. Liver Transpl 12 (2006) S119
22. Schemmer P., Nickkholgh A., Hinz U., et al. Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analysis. Transplant Proc 39 (2007) 529
23. Kootstra G., Kievit J., and Nederstigt A. Organ donors: heartbeating and non-heartbeating. World J Surg 26 (2002) 181
24. Ramos H.C., and Lopez R. Critical care management of the brain-dead organ donor. Curr Opin Org Transpl 7 (2002) 70
25. Fondevila C., and Ghobrial R.M. Donor selection and management. In: Busuttil R.W., and Klintmalm G.K. (Eds). Transplantation of the liver (2005), Elsevier, New York
26. Lake J.R., Shorr J.S., Bettina J., et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transpl 5 (2005) 549
27. Adam R., McMaster P., O'Grady J., et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 9 (2003) 1231
28. Kim D.Y., Cauduro S.P., Bohorquez H.E., et al. Routine use of livers from deceased donors older than 70: is it justified?. Transpl Int 18 (2005) 73
29. Briceno J., Padillo J., Rufian S., et al. Assignment of steatotic livers by the Mayo model for end-stage liver disease. Transplant Int 18 (2005) 577
30. Fishbein T., Fiel M., Emre S., et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 64 (1997) 248
31. Adam R., Reynes M., Johann M., et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 23 (1991) 1538
32. Cacciarelli T.V., Keeffe E.B., Moore D.H., et al. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation. Arch Surg 134 (1999) 25
33. Honore P., Detry O., Meurisse M., et al. Liver transplantation: experience and results of a program at the University of Liege. Rev Med Liege 53 (1998) 735
34. Nemes B., Sarvary E., Sotanyi Z., et al. Factors in association with sepsis after liver transplantation: the Hungarian experience. Transplant Proc 37 (2005) 2227
35. Scatton O., Meunier B., Chequi D., et al. Randomized trial of choledochocholedochostomy with or without a T tube in orthotopic liver transplantation. Ann Surg 233 (2001) 432
36. Urbani L., Campatelli A., Romagnoli J., et al. T-tube removal after liver transplantation: a new technique that reduced biliary complications. Clin Transpl 74 (2002) 410
37. Koneru B., Sterling M.J., and Bahramipour P.F. Bile duct strictures after liver transplantation: a changing landscape of the Achilles' heel. Liver Transpl 12 (2006) 702
38. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 8 (2002) S14
39. Fernandez I., Meneu J.C., Colina F., et al. Clinical and historical efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 12 (2006) 1805
40. Rakela J., and Vergas H.E. Hepatitis C: magnitude of the problem. Liver Transpl 8 (2002) S3
41. Burton J.R., and Rosen H.R. Retransplantation for hepatitis C: what do we really know?. Liver Transpl 10 (2004) 1504
42. Pelletier S.J., Schaubel D.E., Punch J.D., et al. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 11 (2005) 434
43. Wong S.N., Chu C.J., Wai C.T., et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 13 (2007) 364
44. Marzano A., Gaia S., Ghisetti V., et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 11 (2005) 402
45. Tan J., and Lok A.S.F. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 13 (2007) 323
46. Cuadrado A., Fabrega E., Casafont F., et al. Alkohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 11 (2005) 420
47. Faust T.W. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Liver Transpl 7 (2001) S99
48. Gautam M., Cheruvattath R., and Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 12 (2006) 1813
49. Press S.J., Schumacher G., Neuthaus R., et al. De novo esophageal neoplasia after liver transplantation. Liver Transpl 13 (2007) 443
50. Herrero J.I., Espana A., Quiroga J., et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl 11 (2005) 1100
51. Herrero J.I., Lorenzo M., Quiroga J., et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 11 (2005) 89
52. Oruc M.T., Soran A., Jain A.K., et al. De novo breast cancer in patients with liver transplantation: University of Pittsburgh's experience and review of the literature. Liver Transpl 10 (2004) 1